Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Shares Up 6.7 Percent After CEO Laukien Buys $666K Worth of Stock

NEW YORK, May 12 (GenomeWeb News) - Bruker Biosciences CEO Frank Laukien bought more than $666,000 worth of his company's stock since Tuesday, sending the shares up 6.7 percent to $3.83 in mid-afternoon trading today.


According to, which tracks insider trading at public companies, Laukien bought 176,365 shares at prices between $3.60 and $3.80 per share for a total cost of $666,105.30.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.